127 related articles for article (PubMed ID: 33822033)
1. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Ferreira JP; Collier T; Clark AL; Mamas MA; Rocca HB; Heymans S; González A; Ahmed FZ; Petutschnigg J; Mujaj B; Cuthbert J; Rouet P; Pellicori P; Mariottoni B; Cosmi F; Edelmann F; Thijs L; Staessen JA; Hazebroek M; Verdonschot J; Rossignol P; Girerd N; Cleland JG; Zannad F
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):149-156. PubMed ID: 33822033
[TBL] [Abstract][Full Text] [Related]
2. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
3. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Verdonschot JAJ; Ferreira JP; Pellicori P; Brunner-La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Mariottoni B; Petutschnigg J; Rossignol P; Cleland JGF; Zannad F; Heymans SRB;
Cardiovasc Diabetol; 2021 Aug; 20(1):163. PubMed ID: 34372849
[TBL] [Abstract][Full Text] [Related]
4. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
Monzo L; Ferreira JP; Cleland JGF; Pellicori P; Mariottoni B; Verdonschot JAJ; Hazebroek MR; Collier TJ; Cuthbert JJ; Pieske B; Edelmann F; Petutschnigg J; Khan J; Ahmed FZ; Girerd N; Bozec E; Díez J; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Rossignol P; Zannad F
ESC Heart Fail; 2022 Dec; 9(6):4352-4357. PubMed ID: 36065795
[TBL] [Abstract][Full Text] [Related]
5. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Ferreira JP; Verdonschot J; Wang P; Pizard A; Collier T; Ahmed FZ; Brunner-La-Rocca HP; Clark AL; Cosmi F; Cuthbert J; Díez J; Edelmann F; Girerd N; González A; Grojean S; Hazebroek M; Khan J; Latini R; Mamas MA; Mariottoni B; Mujaj B; Pellicori P; Petutschnigg J; Pieske B; Rossignol P; Rouet P; Staessen JA; Cleland JGF; Heymans S; Zannad F;
JACC Heart Fail; 2021 Apr; 9(4):268-277. PubMed ID: 33549556
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
7. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
8. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
[TBL] [Abstract][Full Text] [Related]
9. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira JP; Cleland JGF; Girerd N; Pellicori P; Hazebroek MR; Verdonschot J; Collier TJ; Petutschnigg J; Clark AL; Staessen JA; Heymans S; Rossignol P; Zannad F
Am J Cardiol; 2023 Mar; 191():39-42. PubMed ID: 36634548
[TBL] [Abstract][Full Text] [Related]
10. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
11. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
12. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
[TBL] [Abstract][Full Text] [Related]
13. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
Lim PO; Jung RT; MacDonald TM
Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
16. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
Rosa J; Widimský P; Waldauf P; Zelinka T; Petrák O; Táborský M; Branny M; Toušek P; Čurila K; Lambert L; Bednář F; Holaj R; Štrauch B; Václavík J; Kociánová E; Nykl I; Jiravský O; Rappová G; Indra T; Krátká Z; Widimský J
J Hypertens; 2017 May; 35(5):1093-1099. PubMed ID: 28118281
[TBL] [Abstract][Full Text] [Related]
17. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R
Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085
[TBL] [Abstract][Full Text] [Related]
18. Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial.
Faconti L; Mills CE; Govoni V; Gu H; Morant S; Jiang B; Cruickshank JK; Webb AJ
Br J Clin Pharmacol; 2019 Jan; 85(1):169-180. PubMed ID: 30294825
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
